LyrArc Article Gist
Google Inc. has made an agreement to acquire Motorola Mobility Holdings Inc. for $12.5 billion in cash. This deal puts Google in direct competition with Apple Inc., RIM, and Nokia. Google is taking on new risks with this acquisition. It is known as a software company, and the acquisition puts it in an area with which it has little experience- manufacturing and managing sales of devices working with retailers. It also risks making partners- such as Samsung, HTC Corp., Sony Ericsson, and LG Electronics that make mobile phones- into rivals. Forrester Research points out that this could lead to these companies hedging their bets and also making mobile phones that use the Microsoft operating system. Google considered a similiar plan for entry into the PC market after it developed the Chrome operating system but decided against it, opting instead to work with PC manufacturers Acer Inc and Samsung. The deal brings with it a large number of patents Motorola holds in mobile technology.

LyrArc Article Gist
Abbott Labs will split into two publicly traded companies, with a medical products company including products such as Similac, Ensure and stent devices, and a pharmaceutical company that would have its Humira rheumatoid arthritis therapy Humira. Humira generates about $8 billion in sales, but faces patent expiration in 2016 and competition from a new drrug expected from Pfizer, as well as generics. Abbott's CEO sees the opportunities in the two products falling in different areas. The medical products business has greater potential in emerging markets, and will require a different focus from the slower growing pharmaceutical business facing competition and payor cost pressures. The medical product company includes a drug coated stent Xience, with $1.5 billion in sales, which has improved prospects as J&J is leaving the stent business. The medical products business sales are 40% from emerging markets, and 40% of revenue comes from patients not from cost conscious governments or insurers, according to CEO White. Its the emerging markets emphasis that convinced White to go with the split. Richard Gonzalez who runs the pharmaceutical business will head the pharmaceutical company, and CEO Miles White will run the medical products company....